121800 Advanced Glycation Endproduct-BSA

121800
No pudo obtenerse el precio
La cantidad mínima tiene que ser múltiplo de
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmarDisponibilidad a confirmar
En existencia 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service
      Ver precios y disponibilidad
      Click To Print This Page

      Descripción

      Replacement Information

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      US1121800-10MG
      Comprobando disponibilidad...
      Disponibilidad a confirmarDisponibilidad a confirmar
      En existencia 
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        El resto: se avisará
          El resto: se avisará
          Se avisará
          Póngase en contacto con el Servicio de Atención al Cliente
          Contact Customer Service

          Frasco de vidrio 10 mg
          Recuperando precio...
          No pudo obtenerse el precio
          La cantidad mínima tiene que ser múltiplo de
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          Description
          OverviewPrepared by reacting BSA with glycoaldehyde under sterile conditions. Glycated-BSA shows a 5,000 - 10,000% increase in fluorescence as compared to normal BSA (confirmed by fluorescence spectrophotometry, excitation/emission 370/440 nm). AGE-BSA has been reported to induce apoptosis in cultured human umbilical vein endothelial cells and inhibit nitric oxide synthase activity in proximal tubular epithelial cells. Advanced glycation end products and their receptors have been implicated in the pathogenesis of diabetes, induction of proinflammatory cytokines, and stimulation of smooth muscle proliferation, and fibronectin production.
          Catalogue Number121800
          Brand Family Calbiochem®
          SynonymsAGE-BSA
          References
          ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.
          Product Information
          FormLiquid
          FormulationIn sterile-filtered PBS.
          Applications
          Biological Information
          Purity≥95% by SDS-PAGE
          Concentration Label Please refer to vial label for lot-specific concentration
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Dry Ice Only
          Toxicity Standard Handling
          Storage ≤ -70°C
          Avoid freeze/thaw Avoid freeze/thaw
          Do not freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          Licencias necesarias

          Título
          PRODUCTO REGULADO POR LA SAGARPA
          PRODUCTO REGULADO POR LA SECRETARÍA DE SALUD

          Ficha datos de seguridad (MSDS)

          Título

          Ficha técnica de seguridad del material (MSDS) 

          Certificados de análisis

          CargoNúmero de lote
          121800

          Referencias bibliográficas

          Visión general referencias
          Okamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.

          Folleto

          Cargo
          Caspases and other Apoptosis Related Tools Brochure
          Pathways and Biomarkers of Oxidative Stress
          Ficha técnica

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision08-April-2008 RFH
          SynonymsAGE-BSA
          DescriptionPrepared by reacting bovine serum albumin (BSA) with glycoaldehyde under sterile conditions. Fluorescence of AGE-BSA is confirmed by fluorescence spectrophotometry, excitation/emission = 370/440 nm. Glycated BSA shows a 5000-10,000% increase in fluorescence compared to control BSA. AGE and their receptors have been implicated in the pathogenesis of diabetes, induction of pro-inflammatory cytokines, and stimulation of smooth muscle proliferation and fibronectin production. AGE-BSA has also been shown to induce apoptosis in cultured human umbilical vein endothelial cells (HUVEC) and inhibit nitric oxide synthase activity in proximal tubular epithelial cells of the kidney.
          FormLiquid
          FormulationIn sterile-filtered PBS.
          Concentration Label Please refer to vial label for lot-specific concentration
          Purity≥95% by SDS-PAGE
          Storage ≤ -70°C
          Avoid freeze/thaw
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing initial thaw, aliquot and freeze (-70°C).
          Toxicity Standard Handling
          ReferencesOkamoto, T., et al. 2002. Microvasc. Res. 63, 186.
          Ohgami, N., et al. 2001. J. Biol. Chem. 276, 3195.
          Wang, R., et al. 2001. J. Nippon Med. Sch. 68, 472.
          Sakata, N., et al. 2000. J. Atheroscler. Thromb. 7, 169.
          Verbeke, P., et al. 2000. Biochim. Biophys. Acta 1502, 481.
          Farboud, B., et al. 1999. Mol. Vis. 5, 11.
          Huang, J.-S., et al. 1999. Biochem. J. 342, 231.
          Min, C., et al. 1999. Diabetes Res. Clin. Pract. 46, 197.
          Neumann, A., et al. 1999. FEBS Lett. 453, 283.
          Stitt, A.W., et al. 1999. Biochem. Biophys. Res. Commun. 256, 549.
          Nazaimoon, W. and Bak, K. 1998. Malays. J. Pathol. 20, 83.